AIM: To investigate the hepatoprotective effect of baicalein against carbon tetrachloride (CCl₄)-induced liver damage in mice. METHODS: Mice were orally administered with baicalein after CCl₄ injection, and therapeutic baicalein was given twice a day for 4 d. The anti-inflammation effects of baicalein were assessed directly by hepatic histology and serum alanine aminotranferease and aspartate aminotransferase measurement. Proliferating cell nuclear antigen was used to evaluate the effect of baicalein in promoting hepatocyte proliferation. Serum interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) levels were measured by enzyme-linked immunosorbent assay and liver IL-6, TNF-α, transforming growth factor-α (TGF-α), hepatocyte growth factor (HGF) and epidermal growth factor (EGF) genes expression were determined by quantitative real-time polymerase chain reaction. RESULTS: CCl₄-induced acute liver failure model offers a survival benefit in baicalein-treated mice. The data indicated that the mRNA levels of IL-6 and TNF-α significantly increased within 12 h after CCl₄ treatment in baicalein administration groups, but at 24, 48 and 72 h, the expression of IL-6 and TNF-α was kept at lower levels compared with the control. The expression of TGF-α, HGF and EGF was enhanced dramatically in baicalein administration group at 12, 24, 48 and 72 h. Furthermore, we found that baicalein significantly elevated the serum level of TNF-α and IL-6 at the early phase, which indicated that baicalein could facilitate the initiating events in liver regeneration. CONCLUSION: Baicalein may be a therapeutic candidate for acute liver injury. Baicalein accelerates liver regeneration by regulating TNF-α and IL-6 mediated pathways.
AIM: To investigate the hepatoprotective effect of baicalein against carbon tetrachloride (CCl₄)-induced liver damage in mice. METHODS:Mice were orally administered with baicalein after CCl₄ injection, and therapeutic baicalein was given twice a day for 4 d. The anti-inflammation effects of baicalein were assessed directly by hepatic histology and serum alanine aminotranferease and aspartate aminotransferase measurement. Proliferating cell nuclear antigen was used to evaluate the effect of baicalein in promoting hepatocyte proliferation. Serum interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) levels were measured by enzyme-linked immunosorbent assay and liver IL-6, TNF-α, transforming growth factor-α (TGF-α), hepatocyte growth factor (HGF) and epidermal growth factor (EGF) genes expression were determined by quantitative real-time polymerase chain reaction. RESULTS: CCl₄-induced acute liver failure model offers a survival benefit in baicalein-treated mice. The data indicated that the mRNA levels of IL-6 and TNF-α significantly increased within 12 h after CCl₄ treatment in baicalein administration groups, but at 24, 48 and 72 h, the expression of IL-6 and TNF-α was kept at lower levels compared with the control. The expression of TGF-α, HGF and EGF was enhanced dramatically in baicalein administration group at 12, 24, 48 and 72 h. Furthermore, we found that baicalein significantly elevated the serum level of TNF-α and IL-6 at the early phase, which indicated that baicalein could facilitate the initiating events in liver regeneration. CONCLUSION:Baicalein may be a therapeutic candidate for acute liver injury. Baicalein accelerates liver regeneration by regulating TNF-α and IL-6 mediated pathways.
Authors: J S Campbell; L Prichard; F Schaper; J Schmitz; A Stephenson-Famy; M E Rosenfeld; G M Argast; P C Heinrich; N Fausto Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: F Debonera; X Aldeguer; X Shen; A E Gelman; F Gao; X Que; L E Greenbaum; E E Furth; R Taub; K M Olthoff Journal: J Surg Res Date: 2001-04 Impact factor: 2.192
Authors: L A Morio; H Chiu; K A Sprowles; P Zhou; D E Heck; M K Gordon; D L Laskin Journal: Toxicol Appl Pharmacol Date: 2001-04-01 Impact factor: 4.219
Authors: John M Davis; Keith L Knutson; Michael A Strausbauch; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel Journal: J Immunol Date: 2010-05-21 Impact factor: 5.422
Authors: Lawrence A Scheving; Mary C Stevenson; Jonathan M Taylormoore; Peter Traxler; William E Russell Journal: Biochem Biophys Res Commun Date: 2002-01-11 Impact factor: 3.575
Authors: Mekky M Abouzied; Shaymaa M Mahmoud; Ahmed Wahid; Amr E Ahmed; Ahmed M Okasha; Hanan A Soliman; Sultan S Al Thagfan; Eman Z Attia Journal: J Appl Biomed Date: 2020-05-21 Impact factor: 1.797
Authors: Raymond Wu; Ramachandran Murali; Yasuaki Kabe; Samuel W French; Yi-Ming Chiang; Siyu Liu; Linda Sher; Clay C Wang; Stan Louie; Hidekazu Tsukamoto Journal: Hepatology Date: 2018-10-09 Impact factor: 17.425
Authors: Manuela G Neuman; Samuel W French; Barbara A French; Helmut K Seitz; Lawrence B Cohen; Sebastian Mueller; Natalia A Osna; Kusum K Kharbanda; Devanshi Seth; Abraham Bautista; Kyle J Thompson; Iain H McKillop; Irina A Kirpich; Craig J McClain; Ramon Bataller; Radu M Nanau; Mihai Voiculescu; Mihai Opris; Hong Shen; Brittany Tillman; Jun Li; Hui Liu; Paul G Thomes; Murali Ganesan; Steve Malnick Journal: Exp Mol Pathol Date: 2014-09-11 Impact factor: 3.362